Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Stud
- PDF / 1,045,859 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 82 Downloads / 196 Views
ORIGINAL RESEARCH
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE Yue Yang . Xing-Fu Li . Xiao Zhang . Chun-De Bao . Jian-Kang Hu . Jian-Hua Xu . Xiang-Pei Li . Jian Xu . Dong-Yi He . Zhi-Jun Li . Guo-Chun Wang . Han-Jun Wu . Fei Ji . Lu-Jing Zhan . Cristiano A. F. Zerbini . Zhan-Guo Li Received: July 22, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which has demonstrated significant efficacy in patients with moderately to severely active rheumatoid arthritis (RA). This analysis aims to
Yue Yang, Xing-Fu Li, and Xiao Zhang have contributed equally to this work. Digital Features To view digital features for this article go to: https://doi.org/10.6084/m9.figshare.12807017.
Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s40744020-00231-6) contains supplementary material, which is available to authorized users. Y. Yang Z.-G. Li (&) Peking University People’s Hospital, Beijing, China e-mail: [email protected]; [email protected] X.-F. Li Qilu Hospital of Shandong University, Jinan, China X. Zhang Guangdong General Hospital, Guangzhou, China C.-D. Bao Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China J.-K. Hu Jiangxi Pingxiang People’s Hospital, Pingxiang, China
describe the efficacy and safety of baricitinib in Chinese RA patients with an inadequate response to methotrexate (MTX-IR), and to analyze the effects of baseline characteristics on the efficacy of baricitinib treatment. Methods: In this 52-week, randomized, doubleblind, placebo-controlled study, 231 Chinese patients with moderately to severely active RA who had MTX-IR were randomly assigned to placebo (n = 115) or baricitinib 4 mg once daily (n = 116). The primary endpoint was American College of Rheumatology 20% (ACR20) response at week 12. Other efficacy measures included ACR50, ACR70, Physician’s Global Assessment of Disease Activity, Patient’s Global Assessment of Disease Activity, patient’s
J.-H. Xu The First Affiliated Hospital of Anhui Medical University, Hefei, China X.-P. Li The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China J. Xu First Affiliated Hospital of Kunming Medical University, Kunming, China D.-Y. He GuangHua Hospital, Shanghai, China
Rheumatol Ther
assessment of pain, Disease Activity Score in 28 joints using high-sensitivity C-reactive protein, remission and low disease activity rates according to Simplified Disease Activity Index or Clinical Disease Activity Index, Health Assessment Questionnaire-Disability Index, and mean duration and severity of morning joint stiffness, worst tiredness and worst joint pain were analyzed. Additionally, subgroup analyses were performed across baseline characteristics. Results: Statistically significant improvement in ACR20 response was ach
Data Loading...
